CSIMarket
 
Zymeworks Inc   (ZYME)
Other Ticker:  
 
 
Price: $10.8100 $0.04 0.371%
Day's High: $10.93 Week Perf: -2.17 %
Day's Low: $ 10.62 30 Day Perf: -5.26 %
Volume (M): 1,008 52 Wk High: $ 13.14
Volume (M$): $ 10,892 52 Wk Avg: $8.77
Open: $10.73 52 Wk Low: $6.02



 Market Capitalization (Millions $) 746
 Shares Outstanding (Millions) 69
 Employees 600
 Revenues (TTM) (Millions $) 76
 Net Income (TTM) (Millions $) -119
 Cash Flow (TTM) (Millions $) -243
 Capital Exp. (TTM) (Millions $) 4

Zymeworks Inc
Zymeworks Inc is a biopharmaceutical company that primarily focuses on the development of multifunctional biotherapeutics in the areas of immuno-oncology, oncology, and autoimmune disorders. Their proprietary platforms, Azymetric and EFECT, enable the creation of highly differentiated and optimized bi-specific and multi-specific antibodies.

The Azymetric platform utilizes a unique approach that enables the engineering of antibodies to effectively target two different antigens simultaneously. This platform creates symmetrical antibodies that bind to both antigens with high affinity in a stable configuration, which provides superior disease-fighting capabilities. The Azymetric technology also allows for the creation of bi- and multi-specific antibodies with longer half-lives and reduced immunogenicity compared to traditional antibody therapies.

EFECT is a separate bi-specific antibody platform that is designed to activate the immune system by selectively targeting T-cell receptors on tumor cells. EFECT-engineered antibodies are created by fusing two monoclonal antibodies, one of which binds directly to tumor cells, and the other is designed to engage T-cells.

Zymeworks Inc has a portfolio of product candidates in various stages of development, including zanidatamab (ZYBRESTAT), a bi-specific antibody for the treatment of advanced solid tumors, and ZW25, a bi-specific antibody that targets two different epitopes of the HER2 protein, which is overexpressed in many human cancers.

The company has partnerships and collaborations with other biopharmaceutical companies and research organizations, including Merck, Eli Lilly, Celgene, Kite Pharma, and ImmunoGen. They have also received funding from venture capitalists, investors, and government agencies.

Zymeworks Inc was founded in 2003 and is headquartered in Vancouver, British Columbia, Canada. The company has a workforce of over 400 employees, including experienced scientists, engineers, and clinicians. Zymeworks Inc aims to transform the lives of people living with serious diseases by advancing the science of biotherapeutics.


   Company Address: Suite A Middletown 19709 DE
   Company Phone Number: 274-8744   Stock Exchange / Ticker: NASDAQ ZYME
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Zymeworks Inc

Zymeworks Inc. Faces Financial Setback in Fourth Quarter of 2023

Zymeworks Inc. is a clinical-stage biotechnology company that focuses on developing novel biotherapeutics to address the challenges of treating difficult-to-treat diseases. The company recently reported its financial results for the fourth quarter and year ended December 31, 2023. Unfortunately, the results were disappointing, with a significant decrease in revenue and a larger shortfall per share compared to the previous reporting season.
In the October to December 2023 period, Zymeworks Inc. experienced a drastic decline in revenue, with a decrease of 95.795% to $16.93 million. The shortfall per share also increased to $-0.19, compared to the same period in the previous year when it was $-0.41 per share. However, revenue did show a slight increase of 2.545% from the preceding reporting season.

Clinical Study

Zymeworks Advances Cutting-Edge Therapies at AACR Annual Meeting

Published Tue, Mar 5 2024 9:30 PM UTC

The pharmaceutical industry is witnessing a rapid advancement in the development of innovative biotherapeutics to tackle challenging diseases. Zymeworks Inc., a pioneering biotechnology company, has recently announced the acceptance of five abstracts for poster presentations at the prestigious American Association for Cancer Research (AACR) Annual Meeting. This event, schedu...

Product Service News

Zymeworks Inc. Spearheads Transformation in Biotechnology Landscape with Ambitious Strategic Vision

Published Thu, Jan 4 2024 11:15 AM UTC

In a recent update, Zymeworks Inc., a clinical-stage biotechnology company, has outlined its strategic priorities for 2024 and 2025. This forward-thinking approach aims to revolutionize the standard of care for challenging-to-treat diseases through the development of novel, multifunctional biotherapeutics. Let's delve into the details and assess the potential impact of these...

Product Service News

Zymeworks' Promising Future: Inclusion in Nasdaq Biotechnology Index Amplifies Growth Prospects

Published Fri, Dec 15 2023 1:30 PM UTC



Zymeworks Inc., a clinical-stage biotechnology company focused on developing innovative biotherapeutics, has recently announced its expected inclusion in the highly esteemed Nasdaq Biotechnology Index (NBI). This development, which will come into effect on December 18, 2023, is expected to have a significant impact on Zymeworks' future prospects and overall financi...

Zymeworks Inc

Zymeworks Inc Demonstrates Remarkable Performance Surge in the Third Quarter of 2023

Zymeworks Inc, a clinical-stage biotechnology company, experienced a decline in its stock performance over the past week. The stock went down by -6.46%, contributing to a year-to-date performance of -7.82%. However, despite this recent decline, Zymeworks Inc's stock is still trading 20.7% higher than its 52-week low.
Looking at the company's financial performance, it is evident that Zymeworks Inc has made significant improvements. In the fiscal time-frame ending September 30, 2023, the company decreased its loss per share from $-0.72 to $-0.41 compared to the same period last year. Additionally, the earnings per share improved from $-0.76 in the preceding reporting period. These positive changes indicate a potential turnaround for the company.






 

Zymeworks Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Zymeworks Inc does not provide revenue guidance.

Earnings Outlook
Zymeworks Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com